CYP3A4 and cancer: Overall, 48 patients treated with imatinib (56%) would have been excluded from the DASISION and ENESTnd trials due to serious or poorly controlled medical conditions (n = 44, 51% of patients), inadequate hepatic or renal function (n = 9, 10%), concurrent cancer (n = 1, 1%), concomitant use of therapeutic coumarin derivatives (n = 7, 8%), or receiving treatment with any medicines that are CYP3A4 inhibitors or inducers (n = 7, 8%).